Dopamine D2 Receptor Antagonists

Compounds and drugs that bind to and inhibit or block the activation of DOPAMINE D2 RECEPTORS.

Also Known As:

Dopamine D2 Antagonists; Receptor Antagonists, Dopamine D2; Antagonist, Dopamine D2; Antagonists, Dopamine D2; D2 Antagonist, Dopamine; D2 Antagonists, Dopamine; Dopamine D2 Antagonist; Dopamine D2 Receptor Antagonist

Networked: 122 relevant articles (8 outcomes, 19 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Chemical Actions and Uses
- Pharmacologic Actions: 160
  - Molecular Mechanisms of Pharmacological Action: 24
    - Neurotransmitter Agents: 13181
      - Dopamine Agents: 787
        Dopamine Antagonists: 820
        Dopamine D2 Receptor Antagonists: 122
  - Physiological Effects of Drugs: 1
    - Neurotransmitter Agents: 13181
      - Dopamine Agents: 787
        Dopamine Antagonists: 820
        Dopamine D2 Receptor Antagonists: 122

Experts

1.	Green, Alan I: 3 articles (10/2019 - 01/2016)
2.	Salamone, John D: 2 articles (11/2020 - 10/2010)
3.	Brunette, Mary F: 2 articles (10/2019 - 01/2016)
4.	Ebdrup, Bjørn H: 2 articles (01/2017 - 02/2016)
5.	Adán-Castro, Elva: 1 article (01/2022)
6.	Bertsch, Thomas: 1 article (01/2022)
7.	Busby, Robert W: 1 article (01/2022)
8.	Cai, Xiaokun: 1 article (01/2022)
9.	Clapp, Carmen: 1 article (01/2022)
10.	De Colle, Cyril: 1 article (01/2022)

Related Diseases

1.	Dyspepsia (Indigestion) 03/01/2007 - "Itopride, a dopamine D2 antagonist and acetylcholinesterase inhibitor, significantly improved symptoms in patients with functional dyspepsia in one phase II randomized trial. " 02/23/2006 - "We assessed the efficacy of itopride, a dopamine D2 antagonist with anti-acetylcholinesterase [corrected] effects, in patients with functional dyspepsia. " 04/01/2003 - "The dopamine D2 receptor antagonist levosulpiride is a substituted benzamide derivative, whose gastrokinetic properties are exploited clinically for the management of functional dyspepsia. "
2.	Tourette Syndrome (Tourette's Syndrome) 01/01/2018 - "Dopamine D2 receptor antagonists used to treat Tourette syndrome may have inadequate responses or intolerable side effects. " 04/01/2005 - "The results of this study show that, risperidone, a potent combined serotonin (5-HT2) and dopamine (D2) receptor antagonist, is both effective and safe for the treatment for Tourette's Disorder and chronic tic disorder in children and adolescents." 01/01/2020 - "Sulpiride is a highly selective dopamine D2 receptor antagonist and is commonly used in psychiatric disorders, Tourette syndrome, peptic ulcer disease (PUD), and gastroesophageal reflux disease (GERD). "
3.	Tic Disorders (Tic Disorder) 04/01/2005 - "The results of this study show that, risperidone, a potent combined serotonin (5-HT2) and dopamine (D2) receptor antagonist, is both effective and safe for the treatment for Tourette's Disorder and chronic tic disorder in children and adolescents."
4.	Sialorrhea 06/01/2016 - "The aim of this study was to examine the efficacy of metoclopramide (dopamine D2 antagonist, antiemetic medication) as an option for management of hypersalivation associated with clozapine (HAC). "
5.	Dyskinesias (Dyskinesia) 01/01/2021 - "Striatal TRPV1 activation by acetaminophen ameliorates dopamine D2 receptor antagonist-induced orofacial dyskinesia." 01/01/2021 - "Analysis of the US Food and Drug Administration Adverse Event Reporting System and JMDC insurance claims revealed that acetaminophen prevented the dyskinesia induced by dopamine D2 receptor antagonists. " 01/01/2022 - "Enhancement of adenosine A2A signaling improves dopamine D2 receptor antagonist-induced dyskinesia via β-arrestin signaling." 03/03/1994 - "Pretreatment with the dopamine D1 receptor antagonist SCH 23390 (0.8 mg/kg) and the dopamine D2 receptor antagonist sulpiride (60 mg/kg) reduced the magnitude and the duration of the motor response induced by (+)-PHNO and CY 208-243, respectively, but did not modify the intensity and characteristics of choreic dyskinesias. " 01/01/1990 - "1. Nine Cebus monkeys, 6 with mild spontaneous oral dyskinesia (tongue protrusions), were tested with two dopamine D2 antagonists, remoxipride (a new substituted benzamide) and haloperidol, and with two dopamine agonists, methylphenidate and apomorphine. "

Related Drugs and Biologics

1.	itopride
2.	Haloperidol (Haldol)
3.	Antipsychotic Agents (Antipsychotics)
4.	Serotonin (5 Hydroxytryptamine)
5.	Antiemetics
6.	Risperidone (Risperdal Consta)
7.	Clozapine (Clozaril)
8.	Metoclopramide (Reglan)
9.	Cholinesterase Inhibitors (Anticholinesterases)
10.	Serotonin 5-HT1 Receptor Agonists

Related Therapies and Procedures

1.	Therapeutics
2.	Transcranial Direct Current Stimulation
3.	Drug Therapy (Chemotherapy)
4.	Intravenous Administration
5.	Ligation